IL175661A0 - Glycopegylated factor ix - Google Patents
Glycopegylated factor ixInfo
- Publication number
- IL175661A0 IL175661A0 IL175661A IL17566106A IL175661A0 IL 175661 A0 IL175661 A0 IL 175661A0 IL 175661 A IL175661 A IL 175661A IL 17566106 A IL17566106 A IL 17566106A IL 175661 A0 IL175661 A0 IL 175661A0
- Authority
- IL
- Israel
- Prior art keywords
- glycopegylated factor
- glycopegylated
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52708903P | 2003-12-03 | 2003-12-03 | |
| US53938704P | 2004-01-26 | 2004-01-26 | |
| US59274404P | 2004-07-29 | 2004-07-29 | |
| US61451804P | 2004-09-29 | 2004-09-29 | |
| US62338704P | 2004-10-29 | 2004-10-29 | |
| PCT/US2004/041070 WO2005055950A2 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL175661A0 true IL175661A0 (en) | 2006-09-05 |
Family
ID=34682416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL175661A IL175661A0 (en) | 2003-12-03 | 2006-05-16 | Glycopegylated factor ix |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1694315A4 (en) |
| JP (1) | JP4738346B2 (en) |
| KR (1) | KR101209111B1 (en) |
| AU (1) | AU2004296860B2 (en) |
| BR (1) | BRPI0417341A (en) |
| CA (1) | CA2549413A1 (en) |
| IL (1) | IL175661A0 (en) |
| MX (1) | MXPA06006023A (en) |
| NZ (1) | NZ546733A (en) |
| WO (1) | WO2005055950A2 (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7803777B2 (en) | 2003-03-14 | 2010-09-28 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2560657T3 (en) | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | O-linked glycosylation of G-CSF peptides |
| AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
| KR101146160B1 (en) | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | Polymer-factor ix moiety conjugates |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
| EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
| EP2386571B1 (en) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| CN102719508A (en) * | 2005-08-19 | 2012-10-10 | 诺和诺德公司 | Glycopegylated factor VII and factor VIIA |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| EP2049144B8 (en) * | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| LT2068907T (en) * | 2006-10-04 | 2018-01-10 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| ES2521490T3 (en) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugate of factor VIIa - (poly) sialic acid with a prolonged half-life in vivo. |
| CN101796063B (en) | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | methods of treatment using glycopegylated G-CSF |
| AU2008245524A1 (en) * | 2007-04-26 | 2008-11-06 | Cnj Holdings, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
| ES2551123T3 (en) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| US20110154516A1 (en) * | 2007-10-15 | 2011-06-23 | Stafford Darrel W | Human factor ix variants with an extended half life |
| RU2010131189A (en) * | 2007-12-27 | 2012-02-10 | Бакстер Интернэшнл Инк. (Us) | CHEMICALLY MODIFIED FACTOR IX |
| MX2010009154A (en) | 2008-02-27 | 2010-09-09 | Novo Nordisk As | Conjugated factor viii molecules. |
| SG189790A1 (en) * | 2008-04-16 | 2013-05-31 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| ES2590679T3 (en) | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glycopolyallylation of proteins other than blood coagulation proteins |
| KR101832937B1 (en) | 2009-07-27 | 2018-02-28 | 박스알타 인코퍼레이티드 | Blood coagulation protein conjugates |
| SG10201401194VA (en) | 2009-07-27 | 2014-07-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| PE20121643A1 (en) * | 2009-07-31 | 2012-11-25 | Bayer Healthcare Llc | MODIFIED FACTOR IX POLYPEPTIDES AND USES OF THEM |
| CN102639553A (en) * | 2009-11-24 | 2012-08-15 | 诺沃—诺迪斯克保健股份有限公司 | Method of purifying pegylated proteins |
| EA037095B1 (en) | 2010-07-09 | 2021-02-05 | Биовератив Терапьютикс Инк. | Method of treating hemophilia b and bleeding episodes |
| EA032056B1 (en) | 2010-12-22 | 2019-04-30 | Баксалта Инкорпорейтид | Conjugate of a therapeutic protein and a fatty acid derivative, methods of preparing a conjugate of a therapeutic protein and a fatty acid derivative (embodiments) |
| TW201519900A (en) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | Compositions and methods for inducing immune tolerance to coagulation factor proteins |
| EP3941509A1 (en) | 2019-03-19 | 2022-01-26 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59172425A (en) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| SE9503380D0 (en) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AU744303B2 (en) * | 1997-12-01 | 2002-02-21 | Neose Technologies, Inc. | Enzymatic synthesis of gangliosides |
| CN102180944A (en) * | 2001-10-10 | 2011-09-14 | 诺和诺德公司 | Remodeling and glycoconjugation of peptides |
-
2004
- 2004-12-03 EP EP04813394A patent/EP1694315A4/en not_active Withdrawn
- 2004-12-03 CA CA002549413A patent/CA2549413A1/en not_active Abandoned
- 2004-12-03 BR BRPI0417341-4A patent/BRPI0417341A/en not_active Application Discontinuation
- 2004-12-03 AU AU2004296860A patent/AU2004296860B2/en not_active Ceased
- 2004-12-03 MX MXPA06006023A patent/MXPA06006023A/en active IP Right Grant
- 2004-12-03 WO PCT/US2004/041070 patent/WO2005055950A2/en active Application Filing
- 2004-12-03 NZ NZ546733A patent/NZ546733A/en not_active IP Right Cessation
- 2004-12-03 JP JP2006542888A patent/JP4738346B2/en not_active Expired - Fee Related
-
2006
- 2006-05-16 IL IL175661A patent/IL175661A0/en unknown
- 2006-05-30 KR KR1020067010603A patent/KR101209111B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060123224A (en) | 2006-12-01 |
| AU2004296860B2 (en) | 2010-04-22 |
| EP1694315A2 (en) | 2006-08-30 |
| KR101209111B1 (en) | 2012-12-06 |
| CA2549413A1 (en) | 2005-06-23 |
| WO2005055950A2 (en) | 2005-06-23 |
| BRPI0417341A (en) | 2007-04-17 |
| AU2004296860A1 (en) | 2005-06-23 |
| NZ546733A (en) | 2009-07-31 |
| MXPA06006023A (en) | 2006-08-23 |
| EP1694315A4 (en) | 2009-10-28 |
| WO2005055950A3 (en) | 2005-10-20 |
| JP4738346B2 (en) | 2011-08-03 |
| JP2007513190A (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL175661A0 (en) | Glycopegylated factor ix | |
| DE602004023400D1 (en) | Lies | |
| IL175660A0 (en) | Glycopegylated erythropoietin | |
| DE502004011703D1 (en) | N-heterocyclyl-phenylsubstituierte cyclische ketoenole | |
| DE602004012071D1 (en) | T-hilfe | |
| DE602004020356D1 (en) | Phenoxyessigsäurederivate | |
| DE602004030538D1 (en) | Präzisionssubstratlagerbehälter | |
| SG133617A1 (en) | General electric company | |
| DE502004009243D1 (en) | Spirocyclische cyclohexan-derivate | |
| AU155161S (en) | Case | |
| DE602004027010D1 (en) | Thermotherapiehülle | |
| DE502004003476D1 (en) | Standfuss | |
| DE502004006683D1 (en) | Injection-locked-oscillator-schaltkreis | |
| DE502004011852D1 (en) | Nspritzventil | |
| DE502004004146D1 (en) | Pyrazolverbindungen | |
| DE112004002769D2 (en) | Schienengeführtes transportsystem | |
| GB0311208D0 (en) | Feature based caricaturing | |
| DE602004012262D1 (en) | Benzimidazolonverbindung | |
| DE502004011343D1 (en) | Rotorspinnmaschine | |
| DE602004020525D1 (en) | Imidazolderivate | |
| EP1614695A4 (en) | Polypeptide | |
| DE502004012153D1 (en) | Rotorspinnmaschine | |
| DE10394343D2 (en) | Berührungslose biometrische erkennung | |
| AU155596S (en) | Case | |
| ZA200706129B (en) | Glycopegylated Factor IX |